| __timestamp | Alnylam Pharmaceuticals, Inc. | Pharming Group N.V. |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 4042025 |
| Thursday, January 1, 2015 | 60610000 | 5279557 |
| Friday, January 1, 2016 | 89354000 | 8073913 |
| Sunday, January 1, 2017 | 199365000 | 44864073 |
| Monday, January 1, 2018 | 382359000 | 53488904 |
| Tuesday, January 1, 2019 | 479005000 | 65896361 |
| Wednesday, January 1, 2020 | 588420000 | 69968267 |
| Friday, January 1, 2021 | 620639000 | 92047281 |
| Saturday, January 1, 2022 | 770658000 | 131819000 |
| Sunday, January 1, 2023 | 795646000 | 87501000 |
| Monday, January 1, 2024 | 975526000 |
Unlocking the unknown
In the competitive world of biotechnology, managing operational costs is crucial for success. Alnylam Pharmaceuticals, Inc. and Pharming Group N.V. offer a fascinating study in contrasts when it comes to Selling, General, and Administrative (SG&A) expenses over the past decade.
From 2014 to 2023, Alnylam's SG&A expenses surged by over 1,600%, reflecting its aggressive growth strategy and expansion efforts. By 2023, their expenses reached nearly $796 million, a testament to their commitment to innovation and market presence.
In contrast, Pharming Group N.V. maintained a more conservative approach, with SG&A expenses increasing by approximately 2,100% over the same period. Their 2023 expenses were around $88 million, indicating a more measured growth trajectory.
This comparison highlights the diverse strategies employed by biotech firms in navigating the complex landscape of drug development and commercialization.
Cost Management Insights: SG&A Expenses for Merck & Co., Inc. and Alnylam Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Pharming Group N.V.
Comparing SG&A Expenses: Novartis AG vs Pharming Group N.V. Trends and Insights
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Protagonist Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and Mesoblast Limited
Alnylam Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Dynavax Technologies Corporation Trends and Insights
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and Novavax, Inc.
Intra-Cellular Therapies, Inc. or Pharming Group N.V.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Jazz Pharmaceuticals plc and Pharming Group N.V.
Comparing SG&A Expenses: Pharming Group N.V. vs Catalyst Pharmaceuticals, Inc. Trends and Insights
Breaking Down SG&A Expenses: Pharming Group N.V. vs BioCryst Pharmaceuticals, Inc.